Form 4: Rigel Pharma EVP Discloses Future Tax Withholding

Rigel Pharmaceuticals' EVP, Chief Commercial Officer, David A. Santos, disclosed a future non-discretionary disposition of 5,718 common shares for tax withholding purposes, effective February 2, 2026.

Summary

• David A. Santos, EVP, Chief Commercial Officer of Rigel Pharmaceuticals Inc. (RIGL), reported a disposition of 5,718 shares of common stock.
• The transaction is scheduled for February 2, 2026.
• The shares were disposed of at a price of $36.01 per share.
• The transaction code "F" indicates this was a payment of tax liability by delivering or withholding securities incident to the receipt, exercise, or vesting of a security.
• Following this transaction, Mr. Santos will beneficially own 46,986 shares, which includes 1,000 shares acquired under the Issuer's stock purchase plan.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The transaction is a routine, non-discretionary tax withholding related to executive compensation, not a discretionary sale, and therefore carries no significant positive or negative signal regarding management's view of the company's prospects.

Future Outlook

No specific forward-looking statements or guidance are provided beyond the scheduled transaction date.

Industry Context

StockSavvy.ai notes that routine tax withholdings related to equity compensation are standard practice for executives in the biotechnology and pharmaceutical industries, reflecting the common structure of executive compensation packages.

Comparison to Industry Standards

• StockSavvy.ai observes that tax-related dispositions of shares are a common occurrence across publicly traded companies, including peers in the biotech sector such as Gilead Sciences (GILD) or Amgen (AMGN), where executives frequently have shares withheld upon vesting of restricted stock units or exercise of options to cover tax liabilities.
• The specific deemed price of $36.01 per share for tax purposes is unique to the specific equity award and its valuation at the time of vesting/exercise.

Stakeholder Impact

• Minimal impact on shareholders as this is a routine, non-discretionary tax withholding transaction by an executive.

Key Dates

Keywords

Rigel Pharmaceuticals, RIGL, David A. Santos, insider transaction, Form 4, tax withholding, common stock, executive compensation